Epigenetic repression of oncogenic signaling defines immune-permissive tumor states associated with response to immune checkpoint inhibitors in advanced NSCLC
Abstract Background Immune checkpoint inhibitors (ICI) have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC), yet response rates remain below 40% and currently used biomarkers such as programmed cell death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB) show limited predi...